Pharmaceutical company promotional payments to English general practices: a longitudinal study
The growing scale and concentration of payments and the dominance of one company raises concerns about bias in general practice. Future research should investigate the impact of payments on clinical decision making, but to do so, payment disclosures need enhanced transparency, particularly through including product-specific payment details.
Authors
- Tom Fahey (ORCID: https://orcid.org/0000-0002-5896-5783)
- Piotr Ozierański (ORCID: https://orcid.org/0000-0002-2023-3288)
- Shai Mulinari (ORCID: https://orcid.org/0000-0001-8773-9796)
- James Larkin (ORCID: https://orcid.org/0000-0003-4339-5623)
- Frank Moriarty (ORCID: https://orcid.org/0000-0001-9838-3625)
- Muddassar Malik (ORCID: https://orcid.org/0000-0002-5961-5080)
- M. A. El‐Sharkawy
Institutions
- Cairo University (EG)
- Lund University (SE)
- University of Medicine and Health Sciences (KN)
- University of Bath (GB)
- Marymount University (US)
Publication Details
- Journal
- BJGP Open
- Published
- 2025-08-08
- DOI
- https://doi.org/10.3399/bjgpo.2024.0281
- Primary Topic
- Pharmaceutical industry and healthcare
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vetenskapsrådet